 Drugs such as lacanumab and nanumab dramatically lower levels of beta amyloid in the brains of Alzheimer's disease patients, but do not reverse the course of the illness. Many of the individuals serving on the Alzheimer's Association working group that developed the new guidelines have financial conflicts of interest because they're affiliated with drug companies developing anti-amyloid medications, among others.